Flavopiridol (L86-8275) HCl

Catalog No.S2679 Synonyms: NSC 649890, Alvocidib, HMR-1275, DSP-2033

For research use only.

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.

Flavopiridol (L86-8275) HCl Chemical Structure

CAS No. 131740-09-5

Selleck's Flavopiridol (L86-8275) HCl has been cited by 37 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Other CDK Products

Biological Activity

Description Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Targets
CDK1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
CDK7 [1]
(Cell-free assay)
40 nM 40 nM 40 nM 40 nM 300 nM
In vitro

Flavopiridol is initially found to inhibit the epidermal growth factor receptor and protein kinase A (IC50 = 21 and 122 μM). Flavopiridol is later shown to inhibit cell proliferation, at more physiologically relevant concentrations (IC50 = 66 nM) when Flavopiridol is tested in the National Cancer Institute Development Therapeutics Program panel of 60 human tumor cell lines. [1] Flavopiridol induces G1 arrest with inhibition of CDK2 and CDK4 in human breast carcinoma cells in a time and concentration dependent manner. [2] Short time treatment of Flavopiridol (~12 hours) induce apoptosis in hematopoietic cell lines including SUDHL4, SUDHL6 (B-cell lines), Jurkat and MOLT4 (T-cell lines ), and HL60 (myeloid). [3] In the clonogenic assay, Flavopiridol functions as a highly potent cytotoxic compound with a mean IC70 with 8 ng/mL in 23 human tumor models. [4] A recent study shows Flavopiridol treatment induces a substantial AKT-Ser473 phosphorylation in human glioblastoma T98G cell line. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 tumor cell NF;WPFhRem:uaX\ldoF1cW:wIHHzd4F6 M3W4e2lvcGmkaYTpc44hd2ZiTVPGMVchfHWvb4KgZ4VtdCCycn;sbYZmemG2aX;u MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh2M{KxNUc,OTB6NEOyNVE9N2F-
Mia PaCa-2 cell MXTGeY5kfGmxbjDhd5NigQ>? MlzsTY5pcWKrdHnvckBw\iCPaXGgVIFE[S1{IHPlcIwh[2yxbn;n[Y5q[yCjc4PhfUwhUUN3ME2zOkDPxE1? NWP0TI1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOlM3ODlpPkGxNFY{PjB7PD;hQi=>
A2780 cell Mn:0SpVv[3Srb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKEF{N{iwJINmdGxiY3zvco9o\W6rYzDhd5Nige,:jDDJR|UxRTF3IN88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
HCT116 cell MmjuSpVv[3Srb36gZZN{[Xl? M{TmW2lvcGmkaYTpc44hd2ZiSFPUNVE3KGOnbHygZ4xwdm:pZX7pZ{Bie3OjeTygTWM2OD1zMzFOwG0> NXrkfINKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOlM3ODlpPkGxNFY{PjB7PD;hQi=>
PC3 cell MXvGeY5kfGmxbjDhd5NigQ>? NGGwcVZKdmirYnn0bY9vKG:oIGDDN{Bk\WyuIHPsc45w\2WwaXOgZZN{[XluIFnDOVA:OTBizszN M4HMWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N|YxQTxxYU6=
K562 human leukemia cell NIfsb2tRem:uaX\ldoF1cW:wIHHzd4F6 MV7Jcohq[mm2aX;uJI9nKEt3NkKgbJVu[W5ibHX1b4VucWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTBwMUOg{txO MmG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
MIP human colon carcinoma cell NED2R2ZHfW6ldHnvckBie3OjeR?= MnLQTY5pcWKrdHnvckBw\iCPSWCgbJVu[W5iY3;sc44h[2G{Y3nuc41iKGOnbHygcIlv\SxiSVO1NF0xNjF{IN88US=> MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
A549 human lung carcinoma cell MVvQdo9tcW[ncnH0bY9vKGG|c3H5 MUHJcohq[mm2aX;uJI9nKEF3NEmgbJVu[W5ibIXu[{Bk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVk3KG6P M1fhRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
CACO-2 human colon carcinoma cell NXS4ZZl7WHKxbHnm[ZJifGmxbjDhd5NigQ>? NVnrW4ZtUW6qaXLpeIlwdiCxZjDDRWNQNTJiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME24OkBvVQ>? NEX2bmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
M109 mouse lung carcinoma cell MojJVJJwdGmoZYLheIlwdiCjc4PhfS=> Mk[yTY5pcWKrdHnvckBw\iCPMUC5JI1wfXOnIHz1coch[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF05OCCwTR?= NUH0UVdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
A2780/TAX-R human ovarian carcinoma cell M3K4[3Bzd2yrZnXyZZRqd25iYYPzZZk> NFzhSVlKdmirYnn0bY9vKG:oIFGyO|gxN1SDWD3SJIh2dWGwIH;2ZZJq[W5iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD15ODDuUS=> NXPuSpNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
SKBR-3 human breast carcinoma cell M4S2SXBzd2yrZnXyZZRqd25iYYPzZZk> MlTqTY5pcWKrdHnvckBw\iCVS1LSMVMhcHWvYX6gZpJm[XO2IHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;N{egcm0> NEjJWXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A431 human squamous cell MkC1VJJwdGmoZYLheIlwdiCjc4PhfS=> MoO3TY5pcWKrdHnvckBw\iCDNEOxJIh2dWGwIIPxeYFud3W|IHPlcIwh[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF04PSCwTR?= NX3aSm5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
LX-1 human lung carcinoma M{XzXHBzd2yrZnXyZZRqd25iYYPzZZk> NX\TNYlwUW6qaXLpeIlwdiCxZjDMXE0yKGi3bXHuJIx2dmdiY3HyZ4lvd22jIIDyc4xq\mW{YYTpc44tKEmFNUC9O|Uhdk1? NYLIWYVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF|PD;hQi=>
MLF mouse lung fibroblast cell MUPQdo9tcW[ncnH0bY9vKGG|c3H5 NXrCeVIxUW6qaXLpeIlwdiCxZjDNUGYhdW:3c3WgcJVv\yCoaXLyc4Jt[XO2IHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD15MjDuUS=> NIPkW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
PC3 human prostate carcinoma cell M17DVnBzd2yrZnXyZZRqd25iYYPzZZk> MXPJcohq[mm2aX;uJI9nKFCFMzDoeY1idiCycn;zeIF1\SClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxRTZ4IH7N NFzafII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
MCF-7 human breast carcinoma cell MU\Qdo9tcW[ncnH0bY9vKGG|c3H5 M1;MbWlvcGmkaYTpc44hd2ZiTVPGMVchcHWvYX6gZpJm[XO2IHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;Nk[gcm0> NEHGeoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
LS174T human colon carcinoma cell MnnTVJJwdGmoZYLheIlwdiCjc4PhfS=> NF\qcWxKdmirYnn0bY9vKG:oIFzTNVc1XCCqdX3hckBkd2yxbjDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPU[1JI5O NE\4WGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A2780/TAX-S human ovarian carcinoma cell M{Hh[nBzd2yrZnXyZZRqd25iYYPzZZk> NGrlZ4JKdmirYnn0bY9vKG:oIFGyO|gxN1SDWD3TJIh2dWGwIH;2ZZJq[W5iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD14NTDuUS=> M1zvVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
A2780/DDP-S human ovarian carcinoma cell M4fEUnBzd2yrZnXyZZRqd25iYYPzZZk> MWfJcohq[mm2aX;uJI9nKEF{N{iwM2RFWC2VIHj1cYFvKG:4YYLpZY4h[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF02PiCwTR?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
OVCAR-3 human ovarian carcinoma cell MkT5VJJwdGmoZYLheIlwdiCjc4PhfS=> NGLRO5lKdmirYnn0bY9vKG:oIF;WR2FTNTNiaIXtZY4hd3[jcnnhckBk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVU1KG6P Mn7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
CCRF-CEM human leukemia cell NVv4bIhzWHKxbHnm[ZJifGmxbjDhd5NigQ>? Ml;TTY5pcWKrdHnvckBw\iCFQ2LGMWNGVSCqdX3hckBt\XWtZX3pZUBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OVIhdk1? M4fFVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
Hs 27 human fibroblast cell NWTYSXRbWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHn2RndKdmirYnn0bY9vKG:oIFjzJFI4KGi3bXHuJIZq[nKxYnzhd5Qh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVUyKG6P M4PxfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
HL60 human leukemia cell MV;Qdo9tcW[ncnH0bY9vKGG|c3H5 MlnQTY5pcWKrdHnvckBw\iCKTE[wJIh2dWGwIHzleYtmdWmjIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD12NjDuUS=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
ABAE human fibroblast cell M4PUd3Bzd2yrZnXyZZRqd25iYYPzZZk> MUnJcohq[mm2aX;uJI9nKEGEQVWgbJVu[W5iZnnido9jdGG|dDDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NEWgcm0> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/DDP-R human ovarian carcinoma cell NFvSb4ZRem:uaX\ldoF1cW:wIHHzd4F6 NUnaeZQ6UW6qaXLpeIlwdiCxZjDBNlc5OC:GRGCtVkBpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;M{igcm0> NHnzOWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
HCT116/VM46 human colon carcinoma cell MkLQVJJwdGmoZYLheIlwdiCjc4PhfS=> MlXXTY5pcWKrdHnvckBw\iCKQ2SxNVYwXk12NjDoeY1idiClb3zvckBk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVIyKG6P MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
HCT116 human colon carcinoma cell M3;iSHBzd2yrZnXyZZRqd25iYYPzZZk> NW\EOGFPUW6qaXLpeIlwdiCxZjDIR3QyOTZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxicILvcIln\XKjdHnvckwhUUN3ME2xPEBvVQ>? M1fTSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
HCT116/VP35 human colon carcinoma cell NVroOok6WHKxbHnm[ZJifGmxbjDhd5NigQ>? M3PrS2lvcGmkaYTpc44hd2ZiSFPUNVE3N1[SM{WgbJVu[W5iY3;sc44h[2G{Y3nuc41iKGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF0yPyCwTR?= M{P6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN|E{Lz5zMkG5NFMyOzxxYU6=
LNCaP human prostate carcinoma cell NXXs[GhJWHKxbHnm[ZJifGmxbjDhd5NigQ>? NE\6UXdKdmirYnn0bY9vKG:oIFzOR4FRKGi3bXHuJJBzd3O2YYTlJINiemOrbn;tZUBk\WyuIIDyc4xq\mW{YYTpc44> MnXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN|E{RC:jPh?=
human A2780 cell line NXPuV3prWHKxbHnm[ZJifGmxbjDhd5NigQ>? NXHKSpRyPzJiaB?= NV\5WlRvSW62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubDDsbY5mKHejczDk[ZRmem2rbnXkJIlvKGFid3jvcIUh[2WubDC3NkBpeiCleYTveI95cWOrdImgZZN{[XluIFnDOVA:PzFibl2= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB{N{i2N{c,OTVyMke4OlM9N2F-
human ovarian (A2780) cancer cell NYXj[mxbS3m2b4TvfIlkyqCjc4PhfS=> NY[4VoRSS3m2b4TvfIlkKGWoZnXjeEBwdiCqdX3hckBwfmG{aXHuJEhCOjd6MDmgZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD15MTDuUS=> NGP6WlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGyOVk4OSd-MUWxNlU6PzF:L3G+
ID8 NFPjN2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 NHT2bY5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGlFQCClZXzsd{whUUN3ME2wMlAxP87:TR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{M{iyNUc,OTdzMkO4NlE9N2F-
MCF7 NH7RUFNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF3DSlch[2WubIOsJGlEPTB;MD6wNlbPxE1? M4r0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUKzPFIyLz5zN{GyN|gzOTxxYU6=
Sf9 MnK1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDjfYNtcW5iQT;DSGszKGW6cILld5Nm\CCrbh?= M{HKcmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgZ5lkdGmwIFGvR2RMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUCuNFEz|ryP M{nJOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUC0N|Y3Lz5zN{mwOFM3PjxxYU6=
A2780 MoK2TY5pcWKrdHnvckBw\iClZHutcYVlcWG2ZXSgUnBOKHCqb4PwbI9zgWyjdHnvckBifA>? NFPYdHZKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBPWE1icHjvd5Bpd3K7bHH0bY9vKGG2IITodlE6QSCrbjDoeY1idiCDMke4NEBk\Wyucx?= MoO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
A2780 NWfwdWVFUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhWmJicHjvd5Bpd3K7bHH0bY9vKGG2 NHviOIkzPCCqcoO= M{XkTGlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJHJjKHCqb4PwbI9zgWyjdHnvckBifCC2aIK4NlEhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhOjRiaILz NHnSeG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
A2780 M2D3ZWlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJHJjKHCqb4PwbI9zgWyjdHnvckBifA>? Mk\SNlQhcHK| NU\seYUzUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhWmJicHjvd5Bpd3K7bHH0bY9vKGG2IIPldlgxPy96MUGgbY4hcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgNlQhcHK| NF;3UVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
A2780 NE\nWFVKdmirYnn0bY9vKG:oIHPkb|kudWWmaXH0[YQhWk6DIIDvcFIhS1SGIIDoc5NxcG:{eXzheIlwdiCjdB?= NGjkZYszPCCqcoO= MnTYTY5pcWKrdHnvckBw\iClZHu5MY1m\GmjdHXkJHJPSSCyb3yyJGNVTCCyaH;zdIhwenmuYYTpc44h[XRic3XyNkBqdiCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAzPCCqcoO= NXXPWol7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
A2780 NYK1d5NYUW6qaXLpeIlwdiCxZjDj[Is4NW2nZHnheIVlKFKQQTDwc4wzKEOWRDDwbI9{eGixconsZZRqd25iYYS= MX6yOEBpenN? MoLGTY5pcWKrdHnvckBw\iClZHu3MY1m\GmjdHXkJHJPSSCyb3yyJGNVTCCyaH;zdIhwenmuYYTpc44h[XRic3XyOUBqdiCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAzPCCqcoO= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
A2780 NEm2bG1KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnu MnrsNlQhcHK| M2D2bGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO|ZXSgZZMh[XCyZXHyZY5k\SCxZjDNZ4wyKHC{b4TlbY4hdGW4ZXygZYZ1\XJiMkSgbJJ{ M1PlW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[5PFA6Lz5zOES2PVgxQTxxYU6=
NCI60 MoDhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dB?= NELnPJg4OiCqcoO= M4rWfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xPzR5zszN MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6MEewN{c,OjFyOEC3NFM9N2F-
NCI60 NGTodG5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 MXi3NkBpenN? NYXWc41GSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2k3OCClZXzsd{Bie3Onc4Pl[EBieyCuZYToZYwh\W[oZXP0JIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCOQ{WwQVAvQTB2zszN NVHHSZo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA4ODNpPkKxNFgxPzB|PD;hQi=>
DR-U2OS-GFP MV;S[YR2[3Srb36gc4YhcG:vb3zv[492eyC{ZXPvcYJqdmG2aX;uJIlv M4TFWFAvOSC3TR?= NXXNboNyPTZiaILz M1nrdXJm\HWldHnvckBw\iCqb33vcI9od3W|IILlZ49u[mmwYYTpc44hcW5iaIXtZY4hTFJvVULPV{1ITlBiY3XscJMh\XiycnXzd4lv\yCLLWPj[WkhdnWlbHXhd4Uh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHJCTDVzIHzleoVtKGG2IECuNUB2VSCjZoTldkA2PiCqcoOgZpkhcW2vdX7vZoxwfHSrbne= NUP5clJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NVc1OTdpPkKxOFE4PDF5PD;hQi=>
A2780 NFLs[VlEgXSxdH;4bYNqfHliYXfhbY5{fA>? NF7HWFgzPCCqcoO= MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUCuNFI{|ryP MnLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
MRC5 NXviPWNGS3m2b4TvfIlkcXS7IHHnZYlve3R? NIXhTGM4OiCqcoO= Mn;UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBIUTVyPUCuNFI5|ryP M2SwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CxO|Y4Lz5{M{OwNVc3PzxxYU6=
A2780 MVrDfZRwfG:6aXPpeJkh[WejaX7zeC=> MUi3NkBpenN? MkDBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2wMlAzQc7:TR?= NI\hcFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780 NHmybYxEgXSxdH;4bYNqfHliYXfhbY5{fA>? NULnXlFyPDhiaILz NVrPO4xlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0xNjB|Md88US=> MonvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
MRC5 MWjDfZRwfG:6aXPpeJkh[WejaX7zeC=> MknsOFghcHK| NIDldlhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9NE4xOzoQvF2= NX;GUJBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN|AyPzZ5PD;hQi=>
MRC5 NEjsPWJEgXSxdH;4bYNqfHliYXfhbY5{fA>? MnLNNlQhcHK| MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGdKPTB;MD6wOFnPxE1? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
HMEC1 MYXDfZRwfG:6aXPpeJkh[WejaX7zeC=> MliwNlQhcHK| MnrnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTG1GSzFiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhT0l3ME2wMlA3Oc7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
HMEC1 NVfBRlZbS3m2b4TvfIlkcXS7IHHnZYlve3R? NVXwUHhkPDhiaILz NELsRmhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVUWFMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODZ{zszN MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN|MEG3Olc9N2F-
HMEC1 Mkf4R5l1d3SxeHnjbZR6KGGpYXnud5Q> M1fNNVczKGi{cx?= NF65XWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVUWFMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVAvODZ4zszN Mn;RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
A2780 MXnJcohq[mm2aX;uJI9nKEOGS{mgbY4> MX2yOEBpenN? MWXJcohq[mm2aX;uJI9nKEOGS{mgbY4hcHWvYX6gRVI4QDBiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHJPSVCLSTDDWGQheGixc4Doc5J6dGG2aX;uJIF1KFOnckKgZZQhT0l3MDDjc45k\W62cnH0bY9vKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz NGHsWJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780 M1:1PGNmdGxiY4njcIUh[XK{ZYP0JIlv MViyOEBpenN? NFHSR5VE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEBt\XO|IIToZY4hT0l3MDDh[pRmeiB{NDDodpMh[nliZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{ Mnz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEG3OlcoRjJ|M{CxO|Y4RC:jPh?=
A2780 M1P1dWlvcGmkaYTpc44hd2ZiQ1TLPUBqdg>? MVeyOEBpenN? MlHjTY5pcWKrdHnvckBw\iCFRFu5JIlvKGi3bXHuJGEzPzhyIHPlcIx{KGG|c3Xzd4VlKGG|IHTve45z\We3bHH0bY9vKG:oIF3DUFEh[XRiR1m1NEB1dyB3WFfJOVAh[2:wY3XueJJifGmxbjDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>? NIKyWGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780 NH\WSHdKdmirYnn0bY9vKG:oIFPET|khcW5? NXe4OZlrOjRiaILz M{DuZ2lvcGmkaYTpc44hd2ZiQ1TLPUBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDkc5dvemWpdXzheIlwdiCxZjDISG0zKGG2IFfJOVAhfG9iNWjHTVUxKGOxbnPlcpRz[XSrb36gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN? NIjvOHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780 MWnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmw Ml\ZNlQhcHK| MUnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEF{N{iwJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCSQWLQJINt\WG4YXflJIF1KEeLNUCgeI8hPViJSUWwJINwdmOnboTyZZRqd25iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> NHzrT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
MT4 MnzlRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4S= M3T3PWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCQTDC0MVMhcW6oZXP0[YQhcW5iTWS0JINmdGy|IH3lZZN2emWmIH;uJIRigSB2IIDvd5QhcW6oZXP0bY9vKGK7IICyOEBie3OjeTygSWM2OD1yLkCxOe69VQ>? NF3wbWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
MT4 NVf6NplFS3m2b4TvfIlkcXS7IHHnZYlve3R? NXvtXGNuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVVR2IHPlcIx{NCCLQ{WwQVAvODZ5zszN MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
Sf9 MXrJcohq[mm2aX;uJI9nKEOGS{KvZ5lkdGmwIFWxJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlv NX7xfpU3OTVibXnudy=> M2XxVWlvcGmkaYTpc44hd2ZiQ1TLNk9kgWOuaX6gSVEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JIlve2WldDDj[YxteyC3c3nu[{BWdGmpaITDSmZMVkmYVGDSWHBRWFOTR1utZY1q\GVic4Xid5Rz[XSnIHHmeIVzKDF3IH3pcpMh[nliYYX0c5Ji\GmxZ4LhdIh6NCCLQ{WwQVAvOTQQvF2= M1SzT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
A549 NHjpR3FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 NEPycng{KGSjeYO= MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVA:OC5zNN88US=> M1LNeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
DU145 NHnVO|VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 MWWzJIRigXN? Mn\LRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGVUG0OUBk\WyuczDh[pRmeiB|IHThfZMh[nliU2LCJI1mfGixZDygS2k2OD1yLkG1{txO M2ntXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
KB MmfRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dB?= NEW1XlM{KGSjeYO= M{m2V2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVA:OC5zNt88US=> M3vWOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG0PFA1Lz5{NUmxOFgxPDxxYU6=
KBVIN MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2 MUmzJIRigXN? M4D6VWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1LWTW4h[2WubIOgZYZ1\XJiMzDkZZl{KGK7IGPSRkBu\XSqb3SsJGdKPTB;MD6xPO69VQ>? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
HCT116 NXHvVGp{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeC=> MkLLO|IhcHK| MnXORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIx1cXSncj3HcI8hemWjZ3XueEBj[XOnZDDhd5NigSCrbjDwdoV{\W6lZTDv[kAyOCViZnX0ZYwh[m:4aX7lJJNmenWvLDDFR|UxRTBwMEO0{txO NGmyZlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm4OVMxPSd-Mk[5PFU{ODV:L3G+
HCT116 MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2 M163PFczKGi{cx?= NV2yNoszSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGy2aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTDpckBxemW|ZX7j[UBw\iByLk[yOUUh\mW2YXygZo93cW6nIIPldpVuNCCHQ{WwQVAvODV7zszN NV3lbItlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFU{ODVpPkK2PVg2OzB3PD;hQi=>
Sf9 MUjJcohq[mm2aX;uJI9nKGi3bXHu NIXaXocyOCCvaX7z NGDkcnpKdmirYnn0bY9vKG:oIHj1cYFvKEirc{[teIFo\2WmIFPET|kw[3mlbHnuJHQyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jliY3XscJMhfXOrbnegS3NVNUOWRDDhd{B{fWK|dILheIUh[W[2ZYKgNVAhdWmwczDpckBxemW|ZX7j[UBw\iCdZ3HtcYEuOzKSXVHUVEBjgSCVRGOtVGFITSCjbnHsfZNqeyxiSVO1NF0xNjByMkZOwG0> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 NHvTO3pKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGw M2f2dGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXN4LYTh[4dm\CCFRFu5M4N6[2yrbjDUNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUFTLeIll\SCjczDzeYJ{fHKjdHWsJGlEPTB;MD6wNVHPxE1? M4\3WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
HeLa NGHvfY5EgXSxdH;4bYNqfHliYXfhbY5{fA>? NHPRV5Y4OiCqcoO= NE[yRYdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OC5zMt88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 NWT0dG12UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbh?= MV3Jcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKE5vdHXycYlv[WxiSHnzOk11[WepZXSgR2RMPi:QLYTldo1qdmGuIFfTWE11[WepZXSgZ5lkdGmwIFSzJIV5eHKnc4Pl[EBqdiC|ZkKxJINmdGy|IIXzbY5oKGirc4TvcoUhUDFic4Xid5Rz[XSnLDDJR|UxRTBwM{m1{txO MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 M3jtZ2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5? NU\zbllwUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEirc{[teIFo\2WmIFPET|cw[3mlbHnuJGgwVi22ZYLtbY5idCCJU2SteIFo\2WmIF3BWFEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIHPkb|che3Wkc4TyZZRmKHCncITp[IUtKEmFNUC9NE42OTUQvF2= NXT5NHRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO|ExOzZpPkK3NVcyODN4PD;hQi=>
HCT116 M1H3NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4S= MnTwO|IhcHK| MmTKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44hcW5icILld4Vv[2Vib3[gNE43OjVnIF\CV{Bi\nSncjC3NkBpenNuIFXDOVA:OC5yNUpOwG0> NGP3W3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{OyOlM{Oyd-MkezNlY{OzN:L3G+
HepG2 MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2 MmfvO|IhcHK| MkLxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR|UxRTBwMUS2OO69VQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
KOPN8 M33PfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4S= M{jrbVczKGi{cx?= MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuRUF64JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVA:OC5zOUK2{txO NW\weYZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
SEM MlTKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dB?= NXn5Z4xEPzJiaILz MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOHTTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WuVHn0[ZIuT2yxIHHzd4F6NCCHQ{WwQVAvOjB2M988US=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
UOCB1 NFS5NYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0 MWe3NkBpenN? M37DVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVV;DRlEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OD1yLkKwPFTPxE1? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
KOPN8 NXK3e2lXUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpci=> NVzvZZkyOC53IIXN MYmzJJRwKDJ2IHjydy=> M4e4eGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iS1;QUlgh[2WubIOgZZN{\XO|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJINt\WG4ZXSgVGFTWCCuZY\lcEBifCByLkWgeW0h[W[2ZYKgN{B1dyB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MmnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|UoRjJ7NEC3PVc2RC:jPh?=
KOPN8 MXTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmw NYrFPXhiOC53IIXN MkPpNUBpeg>? M4LzUmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iS1;QUlgh[2WubIOgZZN{\XO|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJINt\WG4ZXSgVGFTWCCuZY\lcEBifCByLkWgeW0heHKnLYTy[YF1\WRid3n0bEBPSUNiZn;yJFEhcHJiYX7kJI1m[XO3cnXkJIFnfGW{IEOgeI8hOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
insect cells MofWTY5pcWKrdHnvckBw\iCqdX3hci=> NH7wOGQzNjVibXnudy=> MYfJcohq[mm2aX;uJI9nKGi3bXHuJGNFUzRxY4njcIlvKERzIHX4dJJme3OnZDDpckBqdnOnY4SgZ4VtdHNiYX\0[ZIhOi53IH3pcpMh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnegZY5idHm|aYOsJGlEPTB;MD6wNu69VQ>? NHnRXVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEezN|A5Pyd-M{C3N|MxQDd:L3G+
TC32 MXvxTHRUKGG|c3H5 NFe5U|hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= M4\TN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M2XRUZFJXFNiYYPzZZk> M3ezZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| M2ntS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NFHLV3lyUFSVIHHzd4F6 M3;4XZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M3XIT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MULxTHRUKGG|c3H5 M3HHWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NH3pfJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NGDZOXJyUFSVIHHzd4F6 M37vPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NEK3cG1yUFSVIHHzd4F6 M1zQTJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= NHLHNIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M3Pib5FJXFNiYYPzZZk> M3XH[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MlzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 M2LCe5FJXFNiYYPzZZk> M2LIc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NH65Z5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NVPFcVh7eUiWUzDhd5NigQ>? MmDZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD NIToTWJyUFSVIHHzd4F6 MonzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ M33DdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Caco-2 NInSe5lVd3irY3n0fUBie3OjeR?= NVnrN5M4PDhiaILz MlGxWI95cWOrdImgZYdicW6|dDDDZYNwNTJiY3XscJMh\GW2ZYLtbY5m\CCjdDC0PEBpd3W{czDifUBqdnS{YXPlcIx2dGG{IFHUVEBkd26lZX70doF1cW:wIIXzbY5oKHSqZTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG|c3H5MEBESzVyPUCuNFbPxE1? NIHRPZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB3Nkm4M{c,S2iHTVLMQE9iRg>?
Caco-2 MnTHSpVv[3Srb36gZZN{[Xl? Mm\qOFghcHK| MmXvSIV1\XKvaX7heIlwdiCxZjDJR|UxKH[jbIXld{Bnd3JiaX7obYJqfGmxbjDv[kBUSVKVLVPvWk0zKGmwZIXj[YQh[3m2b4TvfIlkcXS7IH;mJGNi[29vMjDj[YxteyCjZoTldkA1QCCqb4Xyd{BjgSCqaXfoJINwdnSnboSgbY1i\2mwZzygTWM2OD1yLkW5{txO NIPyVXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB3Nkm4M{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot Cleaved caspase-8 / Cleaved caspase-9 / Cleaved caspase-3 ; p-RNAPII / p-eIF4E / Mnk1 ; p-ERK / ERK / p-p38 / p-4EBP1 / 4EBP1 / p-S6 ; CDK2 / CDK4 / Cyclin A / p21 / p27 / Rb 31193061 24572052
Growth inhibition assay Cell viability 31193061
In vivo At the maximal tolerated dose of 10 mg/kg/day administered p.o. on days 1-4 and 7-11, Flavopiridol effects tumor regression in PRXF1337 and tumor stasis lasting for 4 weeks in PRXF1369. [4] After treatment with 7.5 mg/kg Flavopiridol bolus intravenous (IV) or intraperitoneal on each of 5 consecutive days, 11 out of 12 advanced stage subcutaneous (s.c.) human HL-60 xenografts undergo complete regressions, and animals remain disease-free several months after one course of Flavopiridol treatment. SUDHL-4 s.c. lymphomas treated with flavopiridol at 7.5 mg/kg bolus IV for 5 days undergo either major (two out of eight mice) or complete (four out of eight mice) regression, with two animals remaining disease-free for more than 60 days. The overall growth delay is 73.2%. Daily IV or IP administration of flavopiridol results in peak plasma levels of about 7 µM, followed by a progressive decline to approximately 100 nM in 8 hours.[6]

Protocol (from reference)

Kinase Assay:[1]
  • Recombinant CDKs Kinase Reactions:

    CDKs activities are determined in microtiter plates as follows. Forty μg Gst-Rb are mixed with different amounts of Flavopiridol and unlabeled ATP. Reactions are then started by the addition of an ammonium sulfate cut of the S100 fraction obtained from insect cells expressing recombinant human CDKs. The final reaction conditions are 10 mM MgCl2, 50 mM Tris-HCl (pH 7.5), and 1 mM DTT. The final concentration of ATP is adjusted accordingly. Radiolabeled ATP is used as a phosphoryl donor. The reaction is carried out for 2.5 minutes at 30 °C after addition of enzyme and then terminated with the addition of EDTA. The Gst-Rb is then captured with glutathione-Sepharose and the incorporated radioactivity is determined by liquid scintillation counting.

Cell Research:[2]
  • Cell lines: SUDHL4, SUDHL6, Jurkat, MOLT4, and HL60
  • Concentrations: 0, 100 500, 5000 nM
  • Incubation Time: 14 hours
  • Method: Cells grown at a density of 1 × 106 cells/mL are exposed to Flavopiridol for different concentrations and time periods. DNA is extracted. Briefly, cells are washed once with cold phosphate-buffered saline (PBS) and lysed with 3 mL lysis buffer (5 mM Tris-HCL [pH 7.5]; 20 mM EDTA; 0.5% Triton X-100) for 15 minutes at 4 °C. The chromatin of the cell lysates is isolated by centrifugation (20 minutes at 26,000g, 4 °C). The supernatants containing small DNA fragments are extracted sequentially with phenol, phenol:chloroform (1:1), and chloroform. Nucleic acids are precipitated in 0.5 M NaCl, 90% ethanol at -20 °C overnight. RNA is then digested by bovine RNAaseA (60 μg/mL). After sequential reextraction and reprecipitation, DNA is dissolved in 10 mM Tris-HCL (pH 7.5), 1 mM EDTA, 0.5% sodium dodecyl sulfate (SDS) before electrophoresis on 1.6% agarose gel.
  • (Only for Reference)
Animal Research:[4] [6]
  • Animal Models: Human prostate cancer xenografts, PRXFI337 and PRXFI369, grown s.c. in nude mice [4] Human promyelocytic leukemia HL-60, human B-cell follicular lymphoma SUDHL-4, and acquired immunodeficiency syndrome (AIDS)-r
  • Dosages: 10 mg/kg/d [4]; 7.5 mg/kg/d [6]
  • Administration: p.o.[4]; i.p. or i.v. [6]
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 88 mg/mL
(200.77 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 438.3
Formula

C21H20ClNO5.HCl

CAS No. 131740-09-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00112723 Terminated Drug: alvocidib Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Waldenström Macroglobulinemia National Cancer Institute (NCI) December 2005 Phase 1|Phase 2
NCT00098371 Terminated Drug: alvocidib B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 2
NCT00101231 Terminated Drug: alvocidib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia National Cancer Institute (NCI) October 2004 Phase 1
NCT00058240 Completed Drug: alvocidib B-cell Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2003 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Flavopiridol (L86-8275) HCl | Flavopiridol (L86-8275) HCl supplier | purchase Flavopiridol (L86-8275) HCl | Flavopiridol (L86-8275) HCl cost | Flavopiridol (L86-8275) HCl manufacturer | order Flavopiridol (L86-8275) HCl | Flavopiridol (L86-8275) HCl distributor